HK35196A - Method of reducing immunoglobulin e responses - Google Patents

Method of reducing immunoglobulin e responses

Info

Publication number
HK35196A
HK35196A HK35196A HK35196A HK35196A HK 35196 A HK35196 A HK 35196A HK 35196 A HK35196 A HK 35196A HK 35196 A HK35196 A HK 35196A HK 35196 A HK35196 A HK 35196A
Authority
HK
Hong Kong
Prior art keywords
responses
antagonist
reducing immunoglobulin
human interleukin
immunoglobulin
Prior art date
Application number
HK35196A
Other languages
English (en)
Inventor
Robert L Coffman
Jan Egbert De Vries
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22538655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK35196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Publication of HK35196A publication Critical patent/HK35196A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK35196A 1988-02-02 1996-02-29 Method of reducing immunoglobulin e responses HK35196A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15141388A 1988-02-02 1988-02-02

Publications (1)

Publication Number Publication Date
HK35196A true HK35196A (en) 1996-03-08

Family

ID=22538655

Family Applications (1)

Application Number Title Priority Date Filing Date
HK35196A HK35196A (en) 1988-02-02 1996-02-29 Method of reducing immunoglobulin e responses

Country Status (20)

Country Link
US (1) US5676940A (de)
EP (2) EP0327283B1 (de)
JP (1) JPH03500050A (de)
KR (1) KR900700132A (de)
AT (1) ATE93144T1 (de)
AU (1) AU629536B2 (de)
CA (1) CA1341477C (de)
DE (1) DE68908431T2 (de)
DK (1) DK183590A (de)
ES (1) ES2058490T3 (de)
FI (1) FI903827A0 (de)
HK (1) HK35196A (de)
HU (1) HU211059B (de)
IE (1) IE63097B1 (de)
IL (1) IL89124A (de)
MY (1) MY107079A (de)
NZ (1) NZ227812A (de)
PT (1) PT89573B (de)
WO (1) WO1989006975A1 (de)
ZA (1) ZA89766B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE69006221T2 (de) * 1989-12-04 1994-05-05 Fletcher Starnes H Verfahren zur behandlung von septischem schock.
IL96714A0 (en) * 1989-12-20 1991-09-16 Schering Corp Antibody antagonists of human interleukin-4
US5252677A (en) * 1990-11-20 1993-10-12 Mitsubishi Petrochemical Company Limited Functionalized olefin polymers
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
ATE369853T1 (de) 2001-03-12 2007-09-15 Avanir Pharmaceuticals Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
EP0255547A1 (de) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoklonale Antikörper spezifisch gegen Oberflächen-IgE-Rezeptor, sowie Hybrid-Zellinien zur Herstellung und Verwendung dieser Antikörper
EP0407392B2 (de) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden

Also Published As

Publication number Publication date
DK183590A (da) 1990-09-27
IE63097B1 (en) 1995-03-22
US5676940A (en) 1997-10-14
DK183590D0 (da) 1990-08-01
ES2058490T3 (es) 1994-11-01
HU891044D0 (en) 1990-11-28
PT89573A (pt) 1989-10-04
EP0397764A1 (de) 1990-11-22
DE68908431D1 (de) 1993-09-23
MY107079A (en) 1995-09-30
NZ227812A (en) 1991-09-25
FI903827A0 (fi) 1990-08-01
IL89124A0 (en) 1989-08-15
EP0327283A1 (de) 1989-08-09
JPH03500050A (ja) 1991-01-10
PT89573B (pt) 1994-01-31
IL89124A (en) 1994-10-21
DE68908431T2 (de) 1993-12-23
AU3038389A (en) 1989-08-25
EP0327283B1 (de) 1993-08-18
KR900700132A (ko) 1990-08-11
ATE93144T1 (de) 1993-09-15
CA1341477C (en) 2005-03-29
ZA89766B (en) 1989-09-27
HU211059B (en) 1995-10-30
AU629536B2 (en) 1992-10-08
WO1989006975A1 (en) 1989-08-10
IE890302L (en) 1989-08-02
HUT54214A (en) 1991-01-28

Similar Documents

Publication Publication Date Title
IL89124A0 (en) Method for reducing immunoglobulin e responses
EP0409607A3 (en) Antibody to human interleukin-6 receptor
EP0597829A4 (de) Monoklonaler antikörper gegen einen neuen mit menschlichen tumoren assoziierten antigen.
EP0216454A3 (en) Method of promoting animal growth
ZA898322B (en) Method of preventing or reducing eosinophilia
ES8700568A1 (es) Procedimiento para obtener complejos fviii-vwf para uso te- rapeutico
GB8910263D0 (en) Monoclonal antibodies specific for an immunoglobulin isotype
EP0163141A3 (en) Monoclonal anti-human igg antibody and process for preparing the same
WO1991007986A8 (en) Method of treating septic shock
GB8614308D0 (en) Monoclonal anti-human igg4 antibodies
FI924278A (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20050130